Stocks · News reference
GRAIL Exec Expects Broad Label For Galleri Cancer Test Based On Data Co Has Submitted To FDA
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Grail Exec Expects FDA Decision On Approval For Galleri Cancer Test By Early Q1 2027; Expects Galleri Cancer Test To Be Reimbursed At $500 To $600
Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $130
RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100
RBC Raises Price Target on GRAIL, Inc.
RBC increased its price target for GRAIL, Inc. to $100 from $84 while maintaining a Sector Perform rating.
GRAIL, Inc. 12-Month Price Target Raised to $134.33
Analysts have increased the 12-month price target for GRAIL, Inc. to $134.33, maintaining a consensus "Buy" rating.